Tilray Inc (NASDAQ:TLRY – Get Free Report)’s share price traded up 6.9% during mid-day trading on Friday . The company traded as high as $2.17 and last traded at $2.16. 17,430,049 shares changed hands during trading, a decline of 44% from the average session volume of 30,999,646 shares. The stock had previously closed at $2.02.
Analysts Set New Price Targets
Several research firms have recently weighed in on TLRY. CIBC lowered their price objective on shares of Tilray from $2.25 to $2.00 and set a “neutral” rating for the company in a research note on Wednesday, April 10th. Canaccord Genuity Group decreased their price target on shares of Tilray from $4.25 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, April 10th. Finally, Alliance Global Partners increased their price objective on shares of Tilray from $2.25 to $2.75 and gave the stock a “neutral” rating in a research report on Friday, April 5th.
Read Our Latest Research Report on Tilray
Tilray Price Performance
Institutional Investors Weigh In On Tilray
Institutional investors and hedge funds have recently made changes to their positions in the business. Clear Street Markets LLC bought a new stake in Tilray during the 3rd quarter worth approximately $25,000. Simplicity Wealth LLC purchased a new stake in Tilray in the 1st quarter valued at $28,000. RPO LLC purchased a new stake in Tilray in the 4th quarter valued at $28,000. Great Valley Advisor Group Inc. bought a new position in Tilray during the 3rd quarter valued at $29,000. Finally, Gainplan LLC purchased a new position in Tilray during the 4th quarter worth $28,000. Institutional investors and hedge funds own 9.35% of the company’s stock.
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Further Reading
- Five stocks we like better than Tilray
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- MarketBeat Week in Review – 4/29 – 5/3
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What Are Dividend Contenders? Investing in Dividend Contenders
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.